<DOC>
	<DOCNO>NCT01784211</DOCNO>
	<brief_summary>The purpose study measure much study drug insulin glargine get blood stream long take body get rid . The effect exercise also evaluate . This study two part . In Part A , participant receive daily injection LY2605541 insulin glargine 15 day . Some participant may continue Part B . In Part B , participant receive daily injection LY2605541 insulin glargine without exercise . Part B last 6 day . Participants remain regular physician-prescribed meal time insulin throughout study .</brief_summary>
	<brief_title>A Study LY2605541 Glargine Exercise Participants With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Are male female diagnosis Type I Diabetes Mellitis ( T1DM ) least 12 month receive multiple daily insulin injection . Total daily insulin dose &lt; 1.2 unit per kilogram per day ( U/kg/day ) ; daily basal dose &gt; 0.2 U/kg/day Female participant woman childbearing potential test negative pregnancy time enrollment base urine pregnancy test agree use reliable method birth control study Have body mass index ( BMI ) 18 30 kilogram per meter square ( kg/m^2 ) , inclusive Have fast cpeptide &lt; 0.3 nanomoles per liter ( nmol/L ) Have hemoglobin A1c ( HbA1c ) &lt; 9 % screen Participants T1DM eligible enrollment Part B study meet follow criterion : Have maximal oxygen uptake ( VO2 max ) ≥ 25 milliliter ( ml ) oxygen per kilogram per minute ( O2/kg/min ) ( woman ) ≥ 30 ml O2/kg/min ( men ) Perform regular physical cardiorespiratory activity achieve average total energy expenditure ≥ 500 metabolic equivalent task ( MET ) minute per week last 3 month prior screen Have know allergy LY2605541 , insulin glargine , related compound component formulation Have history current cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine ( apart type 1 diabetes ) , hematological , neurological disorder capable significantly alter absorption , metabolism , elimination drug ; constitute risk take study medication ; interfere interpretation data Have episode severe hypoglycemia past 6 month ( severe hypoglycemia define neurological symptom consistent neuroglycopenia required assistance treatment second party ) Have history hypoglycemia unawareness Regular use intend use overthecounter prescription medication nutritional supplement may affect blood glucose body 's sensitivity insulin promote weight loss within 14 day prior dose Have average weekly alcohol intake exceed 21 unit per week ( male age 65 ) 14 unit per week ( male 65 female ) , unwilling comply study requirement regard alcohol consumption Currently smoke &gt; 5 cigarette per day , unwilling comply study requirement regard smoking use tobacco product Have hemoglobin level &lt; 8.0 millimoles per liter ( mmol/L ) ( male ) &lt; 6.4 mmol/L ( female ) screen Are currently participate weight loss program plan course study Are receive chronic ( lasting longer 14 consecutive day ) systemic glucocorticoid therapy ( exclude topical , intraarticular , intraocular preparation ) receive therapy within 4 week dose Have fast triglyceride &gt; 400 milligram per deciliter ( mg/dL ) ( 4.52 mmol/l ) Have previous history family history deep vein thrombosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>